In this issue:
Does adjuvant imatinib decrease RFS and improve OS
Clinicopathological characteristics of FGFR2b
Efficacy of crizotinib
Safety and efficacy of CT-P6 plus SOX or CapeOX
Impact of intratumoral HER2 heterogeneity on T-DXd efficacy
Replication and cytotoxicity of CF33-hNIS
Increasing NRLNs for node-negative patients
Benefits of NAC for Lauren’s diffuse-type adenocarcinoma
Impact of SMM 6 months after gastrectomy
Clinical outcomes of trastuzumab rezetecan
Please login below to download this issue (PDF)